Mirtazapine in Alzheimer-associated Weight Loss

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect.

The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brugmann University Hospital
• Treatments: Mianserin; Mirtazapine

Criteria

Inclusion Criteria:

• AD or mixed dementia

• documented weight loss

• mirtazapine 30 mg explicitly prescribed against weight loss

Exclusion Criteria:

• no treatment compliance

• other causes of weight loss

• other interventions against weight loss